Trial Profile
Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal oedema
- Focus Adverse reactions
- Acronyms ACME
- 19 Aug 2020 According to clinicaltrials.gov the trial was discontinued because of low enrollment number.
- 19 Aug 2020 Status changed from recruiting to discontinued.
- 08 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.